Gavin Hilary James Wood BA (Hons), ACA Net Worth

The estimated Net Worth of Gavin Wood is at least $681 Thousand dollars as of 20 May 2022. Mr Wood owns over 39,000 units of Adaptimmune Therapeutics Plc stock worth over $103,680 and over the last 5 years he sold ADAP stock worth over $0. In addition, he makes $577,643 as Chief Financial Officer at Adaptimmune Therapeutics Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr ACA ADAP stock SEC Form 4 insiders trading

Mr has made over 3 trades of the Adaptimmune Therapeutics Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 39,000 units of ADAP stock worth $11,310 on 20 May 2022.

The largest trade he's ever made was buying 39,000 units of Adaptimmune Therapeutics Plc stock on 20 May 2022 worth over $11,310. On average, Mr trades about 12,000 units every 86 days since 2020. As of 20 May 2022 he still owns at least 96,000 units of Adaptimmune Therapeutics Plc stock.

You can see the complete history of Mr Wood stock trades at the bottom of the page.

Mr. Gavin Hilary James Wood BA (Hons), ACA biography

Gavin Hilary James Wood BA (Hons), ACA is the Chief Financial Officer at Adaptimmune Therapeutics Plc.

What is the salary of Mr ACA?

As the Chief Financial Officer of Adaptimmune Therapeutics Plc, the total compensation of Mr ACA at Adaptimmune Therapeutics Plc is $577,643. There are 7 executives at Adaptimmune Therapeutics Plc getting paid more, with James Noble having the highest compensation of $2,821,740.

How old is Mr ACA?

Mr ACA is 51, he's been the Chief Financial Officer of Adaptimmune Therapeutics Plc since . There are 14 older and 4 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.

What's Mr ACA's mailing address?

Gavin's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.

Insiders trading at Adaptimmune Therapeutics Plc

Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over $40,532,026 worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth $527,131,726 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of $2,827,332. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth $22,814.

What does Adaptimmune Therapeutics Plc do?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Complete history of Mr Wood stock trades at Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Plc executives and stock owners

Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include:

• James Noble,
  Non-Executive Director
• Adrian Rawcliffe,
  Chief Executive Officer, Director
• William Bertrand,
  Chief Operating Officer
• Helen Tayton-Martin,
  Chief Business Officer
• Adrian G. Rawcliffe,
  CEO, Principal Accounting Officer & Director
• Dr. Helen Katrina Tayton-Martin MBA, Ph.D.,
  Co-Founder & Chief Bus. Officer
• William C. Bertrand Jr.,
  Chief Operating Officer
• Gavin Hilary James Wood BA (Hons), ACA,
  Chief Financial Officer
• David Mott,
  Non-Executive Independent Chairman of the Board
• Tal Zvi Zaks,
  Non-Executive Independent Director
• Elliott Sigal,
  Non-Executive Independent Director
• John Furey,
  Non-Executive Independent Director
• Barbara Duncan,
  Non-Executive Independent Director
• Ali Behbahani,
  Non-Executive Independent Director
• Lawrence Alleva,
  Non-Executive Independent Director
• John Lunger,
  Chief Patient Supply Officer
• Elliot Norry,
  Senior Vice President, Chief Medical Officer
• Gavin Wood,
  Chief Financial Officer
• Dr. Arundathy Nirmalini Pandite M.B.A., M.D.,
  Sr. VP of Clinical Devel.
• Dr. Rafael G. Amado,
  Pres of R&D
• Sébastien Desprez,
  VP of Communications & Corp. Affairs
• Margaret Henry,
  Head of PR & Company Sec.
• Dr. Juli P. Miller Ph.D.,
  VP of Investor Relations
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• Gwendolyn Knowlton Binder S...,
  EVP, Adaptimmune LLC
• Giles Francis Bertram Kerr,
  Director
• Jonathan Kenneth Charles Kn...,
  Director
• Forest Baskett,
  10% owner
• Ian Michael Laing,
  Director
• Rafael Amado,
  President, R&D
• Peter A. Thompson,
  Director
• Peter W. Sonsini,
  10% owner
• Patrick J Kerins,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• M James Barrett,
  10% owner
• Enterprise Associates 14, L...,
  
• Advisors Llc Orbi Med Capit...,
  
• Peter J Barris,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Kristen Hege,
  Director
• Priti Hegde,
  Director
• Andrew R Allen,
  Director
• Cintia Piccina,
  Chief Commercial Officer
• Joanna Elizabeth Brewer,
  Chief Scientific Officer
• Garry E Menzel,
  Director